Company: APM
Filing Date: 2025-01-03
Form Type: 424B5
Source: 0001213900-25-000606
Chunk: 6

Company: Aptorum Group Ltd
Filing Date: 2025-01-03
Form: 424B5
Chunk 6
---
 to treat diseases with unmet medical needs,
particularly in oncology (including orphan oncology indications) and infectious diseases. The pipeline of Aptorum is also enriched through
(i) the establishment of drug discovery platforms that enable the discovery of new therapeutics assets through, e.g. systematic screening
of existing approved drug molecules, and microbiome-based research platform for treatments of metabolic diseases, and (ii) the co-development
of PathsDx Test, a novel molecular-based rapid pathogen identification and detection
diagnostics technology, with Accelerate Technologies Pte Ltd, commercialization arm of the Singapore’s Agency for Science, Technology
and Research.

Based on our evaluation of
preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential
market size, competition in market, the Company decides how to prioritize its resources among projects. Our Lead Projects refer to ALS-4,
SACT-1, and PathsDx Test (formerly known as RPIDD). Overall, our rationale for selecting
Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors
and individual attributes of the Lead Projects themselves.

Our current business consists
of “therapeutics” and “non-therapeutics” segments. However, our focus is on the therapeutics segments. Because
of the risks, costs and extended development time required for successful drug development, we have determined to pursue projects within
our non-therapeutics segments, such as diagnostics technology that may be brought to market and generate revenue more quickly.

Therapeutics Segment.
In our therapeutics segment (“Aptorum Therapeutics Group”), we are currently seeking to develop various drug molecules (including
projects seeking to use extracts or derivatives from natural substances to treat diseases) and certain technologies for the treatment
of human disease conditions to tackle unmet needs, in particular, two of our Lead Projects targeting infectious disease and cancer (including
orphan oncology indications). Aptorum Therapeutics Group is operated through Aptorum’s wholly-owned subsidiary, Aptorum Therapeutics
Limited, a Cayman Islands exempted company with limited liability, whose principal place of business is in Hong Kong and whose subsidiaries
(who we sometimes refer to herein as project companies) are based in the United Kingdom, Singapore and Hong Kong.

<div align='center'>S-1</div>

Non-Therapeutics Segment. The non-therapeutics segment (“Aptorum Non-Therapeutics Group”) refers to diagnostics projects